

THE FUTURE OF HEALTHCARE:

EXCLUSIVE INVESTMENT OPPORTUNITIES IN ASIA'S HEALTHCARE AND MEDICAL CARE GIANTS

<u>O</u>

Friday, 7th March 2025

- Session One 10 am to 12 pm Session Two - 3 pm to 5 pm
- 114 Lavender Street, Ct Hub 2, Lobby 4, 18 Floor Singapore 338729
- Introduction to EUDA

Opportunities To Participate As Partners Or Investors Into A NASDAQ Listed Non-invasive Healthcare And Medical Care Asia & China Based Company.

- ➤ Introduction to Stem Cells
 Growth Opportunities In China & Asia
- Introduction to Gene Therapy and It's Opportunities

By invitation only, please RSVP to +65 8223 1894 to confirm

Our Guest Speakers



Mr. James Tan
Chairman & CEO
8i Capital Ltd



Dr. Wang Tai Hua
Founder & Chairman
Cell Bank Group



Prof. Jiang-Kang Zhu
Director & Chair Professor
Institute of Advanced

Biotechnology,
Southern University of
Science and Technology



SPEAKER'S PROFILE



Mr. James Tan
Chairman & CEO
8i Capital Ltd



- · Chairman & CEO of 8i Acquisition 2 Corp (NASDAQ: LAX)
- Chairman & CEO of 8i Enterprises Acquisition Corp (NASDAQ: JFK)
- Chairman & CEO, Moxian, Inc (NASDAQ: MOXC); 2019 -2021:
 Director of Moxian, Inc.
- Director, Pacific Internet (NASDAQ: PCNTF)
- CEO & Director Vashion Corp, listed on the Singapore Stock Exchange.
- Chairman & CEO, Vashion Group Ltd, listed on the Singapore Stock Exchange.
- Bachelor of Arts degree from National University of Singapore



Dr. Wang Tai Hua
Founder & Chairman
Cell Bank Group

Father of Stem Cell Clinical Application

- Vice Chairman of China Medical Biological Technology Society
- Director of China Neural Stem Cell Transplant and Treatment Centre
- Director of Shandong Red Cross Society
- · Post-doctor of Royal College of Medicine, Denmark
- Member of USA Cancer Society



Prof. Jiang-Kang Zhu

Director & Chair Professor Institute of Advanced Biotechnology, Southern University of Science and Technology

Member, US National Academy of Sciences (2010)

- Director and Chair Professor, Institute of Advanced Biotechnology, Southern University of Science and Technology
- Chairman, Shenzhen Cell and Gene Therapy (CGT) Industry Alliance
- Renowned for pioneering research in Epigenetics, Plant Stress Biology, and Gene Editing Technology
- Ranked #1 worldwide in Life Sciences in the Stanford/Elsevier
 Top 2% Scientists List 2024